European Urology Oncology
Издатель: Elsevier · ISSN 2588-9311 · 93 статей
- Unveiling the Clinical Potential of Prostate Cancer Three-dimensional Models: A Systematic Review
- Re: Contieri R, Paciotti M, Uleri A, et al. Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non–muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe Trial. Eur Urol Oncol 2026;9:404–412
- Reply to Pietro Scilipoti, Giuseppe Rosiello, Andrea Salonia, Alberto Briganti, Marco Moschini, Francesco Montorsi Letter to the Editor re: Roberto Contieri, Marco Paciotti, Alessandro Uleri, et al. Second Transurethral Resection of Bladder Tumor Can Be Safely Omitted in Selected Patients with T1 Non–muscle-invasive Bladder Cancer: Results from the Prospective HuNIRe Trial. Eur Urol Oncol 2026;9:404–12
- Re: Parizi MK, D’Andrea D, Pradere B, et al. Prognostic factors for recurrence and survival after radical cystectomy for non-muscle invasive bladder cancer: a multicenter analysis of 1032 patients. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2026.06.001: Prognostic Factors After Radical Cystectomy for Non–muscle-invasive Bladder Cancer: From Prognostication to Patient Selection
- Reply to Simone Sforza’s Letter to the Editor re: Mehdi Kardoust Parizi, David D’Andrea, Benjamin Pradere, et al. Prognostic Factors for Recurrence and Survival After Radical Cystectomy for Non–muscle-invasive Bladder Cancer: A Multicenter Analysis of 1032 Patients. In press. http://dx.doi.org/10.1016/j.euo.2026.06.001
- Re: Paolo Gontero, Richard Perry, Daisy Bridge, et al. Unmet Treatment Need and Challenges Associated with Comparative Evidence Generation in BCG-unresponsive Non–muscle-invasive Bladder Cancer: An Expert Consensus. Eur Urol Oncol 2026;9:652–9
- Reply to Roberto M. Scarpa’s Letter to the Editor re: Paolo Gontero, Richard Perry, Daisy Bridge, et al. Unmet Treatment Need and Challenges Associated with Comparative Evidence Generation in BCG-unresponsive Non–muscle-invasive Bladder Cancer: An Expert Consensus. Eur Urol Oncol 2026;9(3):652–9
- Re: Stacy Loeb, Mariana Rangel Camacho, Tatiana Sanchez Nolasco, et al. Downstream Impact of Social Media Use and Variable Quality of Online Information About Prostate Cancer. Eur Urol Oncol 2025;8:1648–52
- Re: Andrisha-Jade Inderjeeth, Andrew J Martin, Robert R Zielinski et al. Radiographic Progression Without Prostate-specific Antigen Progression in Metastatic Hormone-sensitive Prostate Cancer: A Retrospective Analysis of the ENZAMET Trial (ANZUP 1304). Eur Urol Oncol. In press. http://dx.doi.org/10.1016/j.euo.2026.01.008
- Efficacy and Safety of Olaparib plus Abiraterone Versus Placebo plus Abiraterone in the Non-BRCA Mutation Subgroup of Patients with Metastatic Castration-resistant Prostate Cancer in the PROpel Trial
- Metastasis-free Survival in High-risk Prostate Cancer: A Valid Surrogate, but Is it Transportable Across Strategies of Unequal Systemic Exposure?
- Machine Learning Models Combining [68Ga]Ga-PSMA-11 PET Radiomics and Clinical Features to Predict Overall Survival for Metastatic Castration-resistant Prostate Cancer Treated with [177Lu]Lu-PSMA Radioligand Therapy
- Re: Luc Delobel, Arnauld Villers, Denis Seguier, et al. Long-term Prediction of Metastatic Recurrence in Patients Candidate to Radical Prostatectomy Using MRI and Targeted Biopsy: Insights into Tumor Zonal Origin. Eur Urol Oncol. In press. http://dx.doi.org/10.1016/j.euo.2026.08.009
- Re: Alfonso Santangelo, Wooju Jeong, Caro Silvani, et al. Long-term Oncological Outcomes of Retzius-sparing Versus Anterior Robot-assisted Radical Prostatectomy: Post Hoc Analysis of a Randomized Cohort. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2026.07.012
- Prostate Cancer Incidence and Disease Characteristics in Transgender Women Receiving Gender-affirming Hormone Therapy: A Systematic Review with Meta-analysis
- Clinical Outcomes of Bladder-sparing Management Versus Early Radical Cystectomy in cT1 Micropapillary Bladder Cancer: A Systematic Review and Meta-analysis
- High Radiographic Response Rates After Metastasis-directed Radiation Therapy in SMARCB1-deficient Renal Medullary Carcinoma
- The Nature of Progression on Active Surveillance for Favorable-risk Gleason Grade Group 2 Prostate Cancer
- Neoadjuvant Therapy in Patients with Upper Tract Urothelial Cancer: An Updated Systematic Review and Meta-analysis
- Re: Alfonso Santangelo, Wooju Jeong, Carlo Silvani, et al. Long-term Oncological Outcomes of Retzius-sparing Versus Anterior Robot-assisted Radical Prostatectomy: Post Hoc Analysis of a Randomized Cohort. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2026.07.012: Retzius-sparing Radical Prostatectomy: A Learning-curve Signal, not a Technique Effect
- Re: Santangelo Alfonso, Jeong Wooju, Silvani, Carlo et al. Long-term Oncological Outcomes of Retzius-sparing Versus Anterior Robot-assisted Radical Prostatectomy: Post Hoc Analysis of a Randomized Cohort. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2026.07.012
- Cured but What’s Next? Rethinking Survivorship Care for Adolescent and Young Adult Testicular Cancer Survivors
- Postinduction Urine Tumor DNA Is Predictive for Response to Maintenance Intravesical Therapy in Non–muscle-invasive Bladder Cancer
- RE: Neal Shore, Noel W. Clarke, Andrew J Armstrong et al.Efficacy of Olaparib Plus Abiraterone for Patients with Metastatic Castration-resistant Prostate Cancer and Single Homologous Recombination Repair Gene Mutations in PROpel. Eur Urol 2026;1055-1060 doi.org/10.1016/j.euo.2026.07.014: A Mutation Is Not a Mechanism: Interpreting PROpel Gene by Gene
- Impact of BRCA2, BRCA1, and Other Individual Homologous Recombination Repair Alterations on Survival in Metastatic Castration-resistant Prostate Cancer
- Clinicopathological Features and Outcomes of Molecularly Confirmed TFE3-rearranged Renal Cell Carcinoma in Adults
- Re: Maximilian Pallauf, Stephan Bronimann, Stanley Rapiey, et al. Integrated Urine and Plasma DNA Analysis for Molecular Staging of Upper Tract Urothelial Carcinoma. Eur Urol Oncol. In press. https://doi.org/10.1016/j.euo.2026.08.008
- Development and Internal Validation of the RMC-COMPASS Clinical Prognostic Model for SMARCB1-deficient Renal Medullary Carcinoma
- Sex-disaggregated Outcomes and Safety Reporting in Perioperative Systemic Therapy for Muscle-invasive Bladder Cancer: A Systematic Review
- Exploring the Limits of Robotic Surgery for Wilms Tumor: A Descriptive Analysis